检索结果-南通市图书馆

Tuning Reaction Processes for the Synthesis of Micron and Nanometer Sized, Single Crystalline Lamellae of Copper 7,7,8,8-tetracyano-p-quinodimethane (phase ii) with Large Area

引用

Nano Research 2009年第8期2卷 630-637页

作者： Yaling Liu Zhuoyu Ji Hongxiang Li Wenping Hu Yunqi Liu Daoben Zhu Beijing National Laboratory for Molecular Sciences Key Laboratory of Organic SolidsInstitute of ChemistryChinese Academy of SciencesBeijing 100190China National Center for Nanoscience and Technology Beijing 100190China Department of Compound Semiconductor Devices and Circuit Institute of MicroelectronicsChinese Academy of SciencesBeijing 100029China

Two simple methods have been demonstrated to obtain large area,single crystalline lamellae of copper-7,7,8,8-tetracyanoquinodimethane(CuTCNQ).The formation of the lamellae was a result of fine tuning of the processes during the synthesis processes of CuTCNQ phase *** facile synthesis of large area single crystalline lamellae suggests bright prospects for the study and understanding of the electrical switching of CuTCNQ by using single crystals of its phase ii,and future applications of the material in memory and switching devices.

关键词： CuTCNQ lamellae single crystals phase ii

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of viscum fraxini-2 in advanced hepatocellular carcinoma:a phase Ⅱ study

引用

The Chinese-German Journal of Clinical Oncology 2010年第8期9卷 452-458页

作者： Mohamed A.Ebrahim Hend A.El-Hadaad Omyma A.Alemam Salah A Keshta Lecturer of Medical Oncology Oncology Center-Mansoura University Lecturer of Clinical Oncology and Nuclear Medicine Faculty of MedicineMansoura University Consultant Oncology and Nuclear Medicine Faculty of MedicineMansoura University

Objective： New systemic therapies are needed to improve the prognosis of patients with advanced-stage hepatocellular carcinoma. The study was conducted to determine the efficacy and safety of viscum fraxini-2 in advanced Hepatocellular carcinoma. Methods： A phase ii study with a two-stage design that enrolled a total of 120 patients with chemotherapy nai＇ve advanced hepatocellular carcinoma. The mistletoe preparation for the study is an aqueous injectable solution that contains one milliliter of viscum fraxini. Two ampoules of viscum fraxini were administered subcutaneously once weekly. Re- suits： Chronic hepatitis C virus infection was the predominant cause of liver disease （60%） in studied cases. According to the response evaluation criteria in solid tumors 24 patients （20%） achieved objective response （including 2 complete responses） and 40 patients （33.3%） achieved stable disease. The median progression free survival for all patients was 4 months （range 1-28 months; 95% CI 3.3：4.7 months）. The median overall survival for all patients was 8 months （range 1-28 months; 95% CI 6.3：9.7 months）. The median survival for patients who achieved responsive or stable disease was 16 months. The toxicity was generally mild and well tolerated, mainly in the form of local reaction and fever. There were no drug related discontinu- ation or toxic deaths. Conclusion： Viscum fraxini-2 is an effective, safe treatment for patients with advanced hepatocellular carcinoma. Further randomized controlled trials are recommended.

关键词： viscum fraxini-2 HCC phase ii

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and toxicity of capecitabine combined with intensitymodulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer

引用

World Journal of Gastrointestinal Oncology 2021年第10期13卷 1532-1543页

作者： Xin Wang Wei-Hu Wang Shu-Lian Wang Yong-Wen Song Yue-Ping Liu Yuan Tang Ning Li Wen-Yang Liu Hui Fang Ye-Xiong Li Dong-Bing Zhao Yihebali Chi Lin Yang Jing Jin Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Radiation Oncology Peking University Cancer Hospital and InstituteBeijing 100001China Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeShenzhen 518116Guangdong ProvinceChina Department of Pancreatic and Gastric Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

BACKGROUND Adjuvant chemoradiotherapy(ACRT)with oral capecitabine and intensitymodulated radiotherapy(IMRT)were well tolerated in a phase I study in patients who had undergone partial or total gastrectomy for locally advanced gastric cancer(GC).This phase ii study aimed to further determine the efficacy and toxicity of this combination after radical resection and D1/D2 lymph node dissection(LND)for patients with locally advanced *** To further determine the efficacy and toxicity of this combination after radical resection and D1/D2 LND for patients with locally advanced *** Forty patients(median age,53 years;range,24-71 years)with pathologically confirmed adenocarcinoma who underwent D1/D2 LND were included in this *** patients received ACRT comprising IMRT(total irradiation dose:45 Gy delivered in daily 1.8-Gy fractions on 5 d a week over 5 wk)and capecitabine chemotherapy(dose:800 mg/m²twice daily throughout the duration of radiotherapy).The primary study endpoint was disease-free survival(DFS),and the secondary endpoints were overall survival(OS),toxic effects,and treatment *** The 3-year DFS and OS were 66.2%and 75%,*** median time to recurrence was 19.5 mo(range,6.1-68 mo).Peritoneal implantation(n=10)was the most common recurrence pattern,and the lung was the most common site of extra-abdominal metastases(n=5).Nine patients developed grade 3 or 4 toxicities during *** patients discontinued ACRT,while eleven underwent ACRT without receiving the entire course of *** were no treatmentrelated *** The ACRT protocol described herein showed acceptable safety and efficacy for patients with locally advanced GC who received radical gastrectomy and D1/2 LND.

关键词： Gastric cancer Radiotherapy Chemoradiotherapy Clinical trial phase ii

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Third-look endoscopy prevents delayed bleeding after endoscopic submucosal dissection under antithrombotic therapy

引用

World Journal of Gastroenterology 2020年第41期26卷 6475-6487页

作者： Ryosuke Ikeda Kingo Hirasawa Chiko Sato Yuichiro Ozeki Atsushi Sawada Masafumi Nishio Takehide Fukuchi Ryosuke Kobayashi Makomo Makazu Masataka Taguri Shin Maeda Endoscopy Division Yokohama City University Medical CenterYokohama 232-0024Japan Endoscopy Division Yokohama Medical University Center HospitalYokohama 232-0024Japan Department of Data Science Yokohama City University School of Data ScienceYokohama 236-0004Japan Division of Gastroenterology Yokohama City University Graduate School of MedicineYokohama 236-0004Japan

BACKGROUND Postoperative delayed bleeding(PDB) after gastric endoscopic submucosal dissection(ESD) is the most common adverse event in patients receiving antithrombotics even with second-look endoscopy. Moreover, with the increasing prevalence of cardiovascular and cerebrovascular diseases in an aging population with associated lifestyle-related diseases, an increasing number of patients receive antithrombotics. Several attempts have been made to prevent PDB in aging population;however, a consensus has yet to be *** To examine the efficacy of third-look endoscopy(TLE) for PDB *** One hundred patients with early gastric neoplasms receiving antithrombotics were prospectively enrolled and subjected to ESD with TLE between February 2017 and July 2019. The primary endpoint was PDB rate, which was compared with our preset threshold. Furthermore, we divided the bleeding period into early-and late-onset PDB(E-PDB and L-PDB, respectively) and analyzed its rate. As a secondary analysis, we compared PDB rates with those of a historical control group, using propensity score matching, and calculated the PDB rates per antithrombotic agent use in each *** In total, 96 patients and 114 specimens were finally evaluated. The overall PDB rate was 7.9%(9/114) [90%CI: 4.7-13.1, P = 0.005], while the late-and early-onset PDB rates(L-PDB and E-PDB) were 5.3% [90%CI: 2.7-9.9, P < 0.0001] and 2.6% [90%CI: 1.1-6.4, P = 0.51], respectively. Propensity score matching generated 58 matched pairs for TLE and control groups. No differences were found in overall PDB incidence(10.3% vs 20.7%, P = 0.12), whereas L-PDB occurrence significantly differed(5.2% vs 17.2%, P = 0.04) between groups. Considering antithrombotics' use, the overall PDB rate was higher for direct oral anticoagulants and multiple antithrombotics in the control group, while L-PDB incidence was lower in the TLE group for these agents(8.7% vs 23.1% and 5.0% vs 29.4%, respectively).CONCLUSION TLE for g

关键词： Endoscopic submucosal dissection Postoperative delayed bleeding Third look endoscopy Antithrombotic agents Late phase bleeding phase ii

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：